keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic colorectal cancer

keyword
https://www.readbyqxmd.com/read/28214976/defining-the-optimal-use-of-ablation-for-metastatic-colorectal-cancer-to-the-liver-without-high-level-evidence
#1
REVIEW
Rafael Diaz-Nieto, Stephen Fenwick, Hassan Malik, Graeme Poston
The role of physical interventions (surgical resection and surgical/radiological ablation) for liver metastases of colorectal cancer has changed dramatically over the last 10-15 years. Whereas in the 1990s, when only those patients with up to three unilobar metastases were considered for any form of such intervention, our present approach to these physical interventions is determined by how much viable disease-free liver can be preserved (most authorities accepting 25-30% disease-free future remnant liver volume) and the possibility of further such interventions if the disease recurs in the liver...
February 2017: Current Treatment Options in Oncology
https://www.readbyqxmd.com/read/28213952/down-regulation-of-kiaa1199-cemip-by-mir-216a-suppresses-tumor-invasion-and-metastasis-in-colorectal-cancer
#2
Dejun Zhang, Lei Zhao, Qiong Shen, Qing Lv, Min Jin, Hong Ma, Xiu Nie, Xiumei Zheng, Shaoyi Huang, Pengfei Zhou, Gang Wu, Tao Zhang
Colorectal cancer is one of the major causes of death from cancer. Metastasis is the leading cause of treatment failure, in which cancer stem cells and circulating tumor cells play crucial roles. Identifying the involved metastatic biomarkers and clarifying the regulation mechanisms are of great importance for targeting tumor metastasis. In the current research, we discovered that KIAA1199, a cell-migration inducing protein, showed higher expression in CD44+ cancer cells from metastatic compared with the paired primary tissues, and was upregulated in colorectal cancer and positively correlated with numbers and mesenchymal phenotype of circulating tumor cells, and predicted shorter progress-free survival...
February 18, 2017: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/28213683/phase-ii-study-of-bevacizumab-and-irinotecan-as-second-line-therapy-for-patients-with-metastatic-colorectal-cancer-previously-treated-with-fluoropyrimidines-oxaliplatin-and-bevacizumab
#3
Hidekazu Kuramochi, Masayuki Ando, Michio Itabashi, Go Nakajima, Kazuyuki Kawakami, Mie Hamano, Eiichi Hirai, Hajime Yokomizo, Ryuji Okuyama, Tatsuo Araida, Kazuhiko Yoshimatsu, Shingo Kameoka, Kazuhiko Hayashi
PURPOSE: Fluorouracil and folinic acid with irinotecan (FOLFIRI) plus bevacizumab (BV) is widely used as second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidines, oxaliplatin, and BV. FOLFIRI requires a CV catheter and an infusion pump, which are inconvenient for patients. Sufficient data are not available for characterizing the effectiveness of fluoropyrimidines beyond first disease progression. In this study, we evaluated the efficacy and safety of irinotecan (CPT-11) plus BV as second-line therapy...
February 17, 2017: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/28213365/fda-approval-summary-tas-102
#4
Leigh Marcus, Steven J Lemery, Sachia Khasar, Emily Wearne, Whitney S Helms, Weishi Yuan, Kun He, Xianhua Cao, Jingyu Yu, Hong Zhao, Yaning Wang, Olen Stephens, Erika Englund, Rajiv Agarwal, Patricia Keegan, Richard Pazdur
FDA approved TAS-102 (Lonsurf, Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In an international, multicenter, double-blinded, placebo-controlled trial (TPU-TAS-102-301, herein referred to as RECOURSE), 800 patients with previously treated mCRC were randomly allocated (2:1) to receive either TAS-102 35mg/m2 orally twice daily after meals on Days 1-5 and 8-12 of each 28-day cycle (n=534) or matching placebo (n=266)...
February 17, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28209749/efficacy-and-safety-of-folfiri-regimen-in-elderly-versus-nonelderly-patients-with-metastatic-colorectal-or-gastric-cancer
#5
Ji-Won Kim, Keun-Wook Lee, Kyu-Pyo Kim, Ju Hyun Lee, Yong Sang Hong, Jeong-Eun Kim, Sun Young Kim, Sook Ryun Park, Byung-Ho Nam, Sang-Hee Cho, Ik-Joo Chung, Young Suk Park, Ho-Suk Oh, Myung-Ah Lee, Hye Jin Kang, Young Iee Park, Eun-Kee Song, Hye Sook Han, Kyu Taeg Lee, Dong Bok Shin, Jung Hun Kang, Dae Young Zang, Jee Hyun Kim, Tae Won Kim
BACKGROUND: Irinotecan-based chemotherapy is a standard backbone of therapy in patients with metastatic colorectal cancer (CRC) or gastric cancer (GC). However, there is still a paucity of information concerning the efficacy and safety of irinotecan-based regimens in elderly patients. PATIENTS AND METHODS: Using the patient cohort (n = 1,545) from the UGT1A1 genotype study, we compared the efficacy and safety between elderly and nonelderly patients with metastatic CRC (n = 934) or GC (n = 611) who received first- or second-line FOLFIRI (irinotecan, leucovorin, and 5-fluorouracil) chemotherapy...
February 16, 2017: Oncologist
https://www.readbyqxmd.com/read/28209746/a-phase-ii-randomized-trial-go27827-of-first-line-folfox-plus-bevacizumab-with-or-without-the-met-inhibitor-onartuzumab-in-patients-with-metastatic-colorectal-cancer
#6
Johanna C Bendell, Howard Hochster, Lowell L Hart, Irfan Firdaus, Joseph R Mace, Joshua J McFarlane, Mark Kozloff, Daniel Catenacci, Jessie J Hsu, Stephen P Hack, David S Shames, See-Chun Phan, Hartmut Koeppen, Allen L Cohn
BACKGROUND: Dysregulated hepatocyte growth factor/mesenchymal-epithelial transition (MET) signaling is associated with poor prognosis and resistance to vascular endothelial growth factor inhibition in metastatic colorectal cancer (mCRC). We report outcomes from a double-blind, multicenter phase II trial of the MET inhibitor onartuzumab in combination with mFOLFOX-6 and bevacizumab for mCRC (GO27827; NCT01418222). MATERIALS AND METHODS: Patients were randomized 1:1 to receive onartuzumab (10 mg/kg intravenously [IV]) or placebo plus mFOLFOX-6 and bevacizumab (5 mg/kg IV)...
February 16, 2017: Oncologist
https://www.readbyqxmd.com/read/28209240/geriatric-factors-and-outcomes-in-metastatic-colorectal-cancer
#7
EDITORIAL
Demetris Papamichael, Matti Aapro
No abstract text is available yet for this article.
February 10, 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28209128/mir-296-inhibits-the-metastasis-and-epithelial-mesenchymal-transition-of-colorectal-cancer-by-targeting-s100a4
#8
Zheng He, Lianhua Yu, Shiyi Luo, Mingzhen Li, Junbo Li, Qi Li, Yi Sun, Chengbin Wang
BACKGROUND: Dysregulation of microRNAs (miRNAs) is actively involved in the pathogenesis and tumorigenicity of colorectal cancer (CRC). miR-296 was found to play either oncogenic or tumor suppressive role in human cancers. However, the status of miR-296 and its function in CRC remain unknown. METHODS: The expression of miR-296 was confirmed by qRT-PCR in CRC tissues and cells, and its level was altered by corresponding miRNA vectors. Wound healing and Transwall assays were performed to detect the migration and invasion of CRC cells...
February 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28208209/the-emergence-of-tnik-inhibitors-in-cancer-therapeutics
#9
REVIEW
Tesshi Yamada, Mari Masuda
The outcome of patients with metastatic colorectal cancer remains unsatisfactory. To improve patient prognosis, it will be necessary to identify new drug targets based on molecules that are essential for colorectal carcinogenesis, and to develop therapeutics that target such molecules. The great majority of colorectal cancers (>90%) have mutations in at least one Wnt signaling pathway gene. Aberrant activation of Wnt signaling is a major force driving colorectal carcinogenesis. Several therapeutics targeting Wnt pathway molecules, including porcupine, frizzled receptors, and tankyrases, have been developed, but none of them have yet been incorporated into clinical practice...
February 16, 2017: Cancer Science
https://www.readbyqxmd.com/read/28207849/inhibition-of-peritoneal-dissemination-of-colon-cancer-by-hyperthermic-co2-insufflation-a-novel-approach-to-prevent-intraperitoneal-tumor-spread
#10
Yuanfei Peng, Hua Yang, Qing Ye, Houming Zhou, Minhua Zheng, Yinghong Shi
BACKGROUND: The increasing use of laparoscopic surgery for advanced gastrointestinal cancer raises concerns about intra-peritoneal tumor spread. Prevention of peritoneal dissemination is extremely important but a preventive modality is lacking. The aim of this study was to examine a novel approach (hyperthermic CO2 insufflation, HT-CO2) for preventing peritoneal dissemination during laparoscopic surgery. METHODS: A peritoneal dissemination model was established in Balb/c nu/nu mice by intraperitoneal injection of human colon cancer cells (SW1116, 1×106)...
2017: PloS One
https://www.readbyqxmd.com/read/28205261/stent-placement-prior-to-initiation-of-chemotherapy-in-patients-with-obstructive-nonoperative-left-sided-tumors-is-associated-with-fewer-stomas
#11
Javier Suárez, Gabriel Marín, Ruth Vera, Dorin Colibaseanu, Juan J Vila, Miguel A Ciga, Begoña Oronoz
BACKGROUND AND OBJETIVES: Due to the potential risks associated with stent placement, European Society Gastrointestinal Endoscopy does not recommend prophylactic insertion of stents in patients without symptoms. The aim was to compare complication rates, need of surgery, colostomy formation, and survival between stent placement prior to start of chemotherapy (SEMS group) and upfront ChT (ChT group) in patients with endoscopically non-transverable metastatic left-sided colorectal cancer...
February 15, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28203302/antiangiogenic-therapy-for-refractory-colorectal-cancer-current-options-and-future-strategies
#12
REVIEW
Rachel Riechelmann, Axel Grothey
Even though significant improvements in the treatment of colorectal cancer (CRC) have been made in recent years, survival rates for metastatic colorectal cancer (mCRC) are poor. Effective treatment options for metastatic colorectal cancer remain limited, and new therapeutic strategies are desperately needed. Several tyrosine kinase inhibitors (TKIs) and monoclonal antibodies (mAbs) that target angiogenesis, a critical process for facilitating tumor cell growth, invasion, and metastasis, are either approved or in clinical development for the treatment of mCRC...
February 2017: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/28203168/a-complete-response-case-in-a-patient-with-multiple-lung-metastases-of-rectal-cancer-treated-with-bevacizumab-plus-xeliri-therapy
#13
Hiroki Hashida, Hironaga Satake, Satoshi Kaihara
It has been reported that many patients with lung metastasis of colorectal cancer (CRC) underwent chemotherapy with fluorouracil, folinic acid, oxaliplatin, irinotecan, or capecitabine. There is a small number of reports about the capecitabine and irinotecan (XELIRI) plus bevacizumab (BV) therapy for patients with metastatic CRC in Japan. We report a case of successful BV+XELIRI therapy for rectal cancer with multiple lung metastases as first-line chemotherapy. A 53-year-old female presented with advanced rectal cancer and metastatic lung tumors...
January 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28201998/clinical-performance-evaluation-of-a-sensitive-rapid-low-throughput-test-for-kras-mutation-analysis-using-formalin-fixed-paraffin-embedded-tissue-samples
#14
Christine Weyn, Sofie Van Raemdonck, Robina Dendooven, Vincent Maes, Karen Zwaenepoel, Suzan Lambin, Patrick Pauwels
BACKGROUND: Testing for KRAS mutations in metastatic colorectal cancer (mCRC) on formalin-fixed, paraffin embedded (FFPE) tumor tissue has become standard of care. Different molecular methods exist to determine hotspot KRAS mutations in exon 2, 3 and 4, but testing is often limited by the sensitivity and the speed of analysis. The aim of this retrospective study was to establish the clinical performance of the Idylla™ KRAS Mutation Test on FFPE tumor samples of patients with mCRC. METHODS: KRAS mutation analysis was performed using the therascreen KRAS on the RotorGene Q platform (CE-IVD; Qiagen) and results were subsequently compared to the Idylla™ KRAS Mutation Test...
February 16, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28199979/atm-mutations-and-e-cadherin-expression-define-sensitivity-to-egfr-targeted-therapy-in-colorectal-cancer
#15
Anna-Lena Geißler, Miriam Geißler, Daniel Kottmann, Lisa Lutz, Christiane D Fichter, Ralph Fritsch, Britta Weddeling, Frank Makowiec, Martin Werner, Silke Lassmann
EGFR-targeted therapy is a key treatment approach in patients with RAS wildtype metastatic colorectal cancers (CRC). Still, also RAS wildtype CRC may be resistant to EGFR-targeted therapy, with few predictive markers available for improved stratification of patients. Here, we investigated response of 7 CRC cell lines (Caco-2, DLD1, HCT116, HT29, LS174T, RKO, SW480) to Cetuximab and correlated this to NGS-based mutation profiles, EGFR promoter methylation and EGFR expression status as well as to E-cadherin expression...
February 9, 2017: Oncotarget
https://www.readbyqxmd.com/read/28197947/targeted-therapies-in-elderly-patients-with-metastatic-colorectal-cancer-a-review-of-the-evidence
#16
REVIEW
Gonzalo Tapia Rico, Amanda R Townsend, Vy Broadbridge, Timothy J Price
Metastatic colorectal cancer (mCRC) is the third leading cause of cancer deaths worldwide. As the population of the western world ages, the incidence of colorectal tumours among elderly patients is increasing and consequently so is the demand for treatments for elderly patients. Unfortunately, elderly patients (≥65 years) often go untreated and they are also under-represented in clinical trials. Yet there is some evidence suggesting that 'fit' elderly patients have similar outcomes and tolerance to chemotherapy treatment to their younger counterparts (although the definition of fitness in the elderly population is still a matter of debate)...
February 14, 2017: Drugs & Aging
https://www.readbyqxmd.com/read/28197787/dermatux-phase-iv-trial-of-cetuximab-plus-folfiri-in-first-line-metastatic-colorectal-cancer-receiving-a-pre-defined-skin-care
#17
Carl Christoph Schimanski, Frank Staib, Thomas Göhler, Holger Hebart, Michael Heike, Michael Neise, Jochen Rudi, Thomas Geer, Gerrit Dingeldein, Claudia Lang, Peter Ehscheidt, Thomas Flohr, Klaus Maria Josten, Meinolf Karthaus, Alexander Schmittel, Jan Wierecky, Emil Boller, Martin Indorf, Marcus-Alexander Wörns, Peter R Galle, Markus Moehler
PURPOSE: Cetuximab-induced skin rash Gd3+ occurs in ≥16% patients (pts) (Heinemann et al., Lancet Oncol 15(10):1065-1075, 2014; Van Cutsem et al. J Clin Oncol 27(19):3117-25; 2009b). Survival, response, and toxicity parameters were re-evaluated under a pre-defined skin prophylaxis consistent of vitamin K1 ointment and oral doxycycline. METHODS: This is a national, multicenter, phase 4, first-line mCRC (K-RAS wt) trial. Pts received irinotecan 180 mg/m² (d1), FA 400 mg/m² (d1), 5-FU 400 mg/m² (d1), 5-FU 2400 mg/m² (d1-2), and cetuximab [400 mg/m² (d1), and then 250 mg/m² qw], prophylactic 0...
February 14, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28197686/pre-therapeutic-factors-for-predicting-survival-after-radioembolization-a-single-center-experience-in-389-patients
#18
K J Paprottka, F Schoeppe, M Ingrisch, J Rübenthaler, N N Sommer, E De Toni, H Ilhan, M Zacherl, A Todica, P M Paprottka
PURPOSE: To determine pre-therapeutic predictive factors for overall survival (OS) after yttrium (Y)-90 radioembolization (RE). METHODS: We retrospectively analyzed the pre-therapeutic characteristics (sex, age, tumor entity, hepatic tumor burden, extrahepatic disease [EHD] and liver function [with focus on bilirubin and cholinesterase level]) of 389 consecutive patients with various refractory liver-dominant tumors (hepatocellular carcinoma [HCC], cholangiocarcinoma [CCC], neuroendocrine tumor [NET], colorectal cancer [CRC] and metastatic breast cancer [MBC]), who received Y-90 radioembolization for predicting survival...
February 14, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28196490/rechallenge-and-maintenance-therapy-using-cetuximab-and-chemotherapy-administered-to-a-patient-with-metastatic-colorectal-cancer
#19
Jian Ma, Quan-Liang Yang, Yang Ling
BACKGROUND: Cetuximab combined with chemotherapy is one of the first-line treatments of metastatic colorectal cancer. Although disease progression inevitably occurs, rechallenge and maintenance therapies using cetuximab-based regimens may be beneficial, particularly for patients with wild-type (WT) KRAS. CASE PRESENTATION: A 47-year-old female patient who underwent right hemicolectomy presented with an ulcerative adenocarcinoma (grade 2) revealed by histopathological analysis...
February 14, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28193644/tumour-thrombus-of-the-inferior-vena-cava-extending-into-the-right-atrium-in-the-setting-of-colon-cancer
#20
Daniel Meyers, Nancy A Nixon, Angela Franko, Danny Ng, Vincent C Tam
Tumour thrombus is seen in renal cell and hepatocellular carcinoma, but is rarely reported in colorectal cancer. A woman aged 46 years, with metastatic colonic adenocarcinoma, was found to have a large mass in the inferior vena cava (IVC) extending into the right atrium. Although this lesion was initially thought to be bland thrombus, imaging with contrast-enhanced CT scan and contrast-enhanced ultrasound supported the diagnosis of tumour thrombus. Despite the large size of the lesion, the patient was asymptomatic...
February 13, 2017: BMJ Case Reports
keyword
keyword
27670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"